Skip to content

HIV/HCV co-infected patients respond to re-treatment with pegylated interferon plus ribavirin

Safer crack-smoking resources as a viable addition to comprehensive harm reduction programs for reducing HIV and HCV transmission

Final results confirm twice-daily boosted fosamprenavir is comparable to twice-daily Kaletra in treatment-naive

HIV/HCV coinfected patients more prone to end-stage liver disease without treatment

HIV-positive gay men and sexual transmission of HCV - fisting is key

Low CD4 cell count and hepatitis C coinfection risk factors for acute kidney failure in HIV-infected patients

Spanish study confirms that tenofovir-related kidney problems are rare and linked to other risk factors

85% of rural Chinese HIV-positives also have hepatitis C

Fatty liver prevalence high with HIV/HCV coinfection: 'use ddI or d4T cautiously'